Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study

Rina Hui(The University of Sydney), Mustafa Özgüroğlu(Istanbul University-Cerrahpaşa), Augusto Villegas(Florida Cancer Specialists & Research Institute), Davey B. Daniel(Sarah Cannon), David Vicente(Hospital Universitario Virgen Macarena), Shuji Murakami(Kanagawa Prefectural Hospital Organization), Takashi Yokoi(Kansai Medical University), Alberto Chiappori(Moffitt Cancer Center), Ki Hyeong Lee(Chungbuk National University Hospital), Maike de Wit(Vivantes Klinikum), Byoung Chul Cho(Yonsei University), Jhanelle E Gray(Moffitt Cancer Center), Anna Rydén(AstraZeneca (Sweden)), Louis Viviers(IQVIA (France)), Lynne Poole(AstraZeneca (United Kingdom)), Yiduo Zhang(AstraZeneca (United States)), Phillip A. Dennis(AstraZeneca (United States)), Scott Antonia(Moffitt Cancer Center)
The Lancet Oncology
October 7, 2019
10.1016/s1470-2045(19)30519-4
Cited by 191Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis